{"success":true,"data":{"pressRelease":{"id":"182468","rtpr_id":"nGNX960hxH-20261028","ticker":"SIGA","exchange":"NASDAQ","all_tickers":["SIGA"],"title":"SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX®","author":"Globe Newswire","published_at":"2026-10-28T11:30:00.136Z","article_body":"NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA)\n(Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced\nthat Public Services and Procurement Canada (PSPC) has awarded SIGA a new\ncontract for the procurement of oral TPOXX® (tecovirimat), an antiviral\nmedication used to treat smallpox, on behalf of the Canadian Department of\nNational Defence (CDND) through its Strategic Medical Countermeasures Program.\nThe contract provides for the purchase of up to approximately $15 million by\nMarch 31, 2031, of which approximately $9 million represents firm commitments\nover the first three years of the contract and approximately $6 million is\nsubject to option exercise by the CDND.\n\nThis contract is the second contract for TPOXX® awarded by PSPC on behalf of\nCDND. In April 2020, PSPC awarded a contract for the purchase of up to\napproximately $14 million of oral TPOXX®, and the final delivery under that\ncontract was made in 2025.\n\nCanada's Defence Industrial Strategy recognizes the importance of maintaining\naccess to critical medical countermeasures as part of Canada's broader health\nsecurity and defence preparedness objectives. By securing continued access to\nTPOXX®, this contract helps Canada deliver on that commitment while ensuring\nthat the Canadian Armed Forces have access to an approved medical\ncountermeasure against smallpox.\n\n\"Canada has been a consistent leader in smallpox preparedness, and this award\nreflects its sustained commitment to ensuring its military is ready to respond\nto a potential outbreak,\" said Diem Nguyen, Chief Executive Officer. \"Canadian\nArmed Forces members are often among the first called upon in a public health\nemergency, and ready access to an approved smallpox antiviral helps ensure\nthey can safely and effectively carry out that mission. We are proud to\ncontinue supporting Canada and look forward to further strengthening our\nrelationships with other governments around the world as we do our part to\nhelp protect populations from smallpox.\"\n\nOral TPOXX® was approved by Health Canada for the treatment of smallpox in\nNovember 2021.\n\nABOUT SIGA\n\nSIGA is a commercial-stage pharmaceutical company and leader in global health\nfocused on the development of innovative medicines to treat and prevent\ninfectious diseases. With a primary focus on smallpox, we are dedicated to\nprotecting humanity against the world’s most severe infectious diseases,\nincluding those that occur naturally, accidentally, or intentionally. Through\npartnerships with governments and public health agencies, we work to build a\nhealthier and safer world by providing essential countermeasures against these\nglobal health threats. For more information about SIGA, visit www.siga.com.\n\nFORWARD-LOOKING STATEMENTS\n\nThis press release contains “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act of 1995, as amended,\nincluding statements relating to SIGA’s future business development and\nplans. Forward-looking statements include statements regarding our future\nfinancial position, business strategy, budgets, projected costs, plans and\nobjectives of management for future operations, and delivering products to\ndomestic and international customers under procurement contracts. The words\n“may,” “continue,” “estimate,” “intend,” “plan,”\n“will,” “believe,” “project,” “expect,” “seek,”\n“anticipate,” “could,” “should,” “target,” “goal,”\n“potential” and similar expressions may identify forward-looking\nstatements, but the absence of these words does not necessarily mean that a\nstatement is not forward-looking. Such forward-looking statements are subject\nto various known and unknown risks and uncertainties, and SIGA cautions you\nthat any forward-looking information provided by or on behalf of SIGA is not a\nguarantee of future performance. SIGA’s actual results could differ\nmaterially from those anticipated by such forward-looking statements due to a\nnumber of factors, some of which are beyond SIGA’s control, including, but\nnot limited to, (i) the risk that SIGA is not able to secure in a timely\nmanner new contracts with the U.S. Government to substantially maintain or\nexpand the U.S. Government stockpile of TPOXX®, (ii) the risk that SIGA may\nnot complete remaining performance under the 19C BARDA Contract (the \"BARDA\nContract\"), with the U.S. Biomedical Advanced Research and Development\nAuthority (\"BARDA\") on schedule or in accordance with contractual terms, (iii)\nthe risk that the nascent international biodefense market does not develop to\na degree that allows SIGA to continue to successfully market TPOXX®\ninternationally, (iv) the risk that potential products, including potential\nalternative uses or formulations of TPOXX® that appear promising to SIGA or\nits collaborators, cannot be shown to be efficacious or safe in subsequent\npre-clinical or clinical trials, (v) the risk that target timing for\ndeliveries of product to customers, and the recognition of related revenues,\nare delayed or adversely impacted by the actions, or inaction, of contract\nmanufacturing organizations, or other vendors, within the supply chain, or due\nto coordination activities between the customer and supply chain vendors, (vi)\nthe risk that SIGA or its collaborators will not obtain or maintain\nappropriate or necessary governmental approvals to market these or other\npotential products or uses, (vii) the risk that any challenge to SIGA’s\npatent and other property rights, if adversely determined, could affect\nSIGA’s business and, even if determined favorably, could be costly, (viii)\nthe risk that regulatory requirements applicable to SIGA’s products may\nresult in the need for further or additional testing or documentation that\nwill delay or prevent SIGA from seeking, obtaining or maintaining needed\napprovals to market these products, (ix) the risk that changes in domestic or\nforeign economic and market conditions may affect SIGA’s ability to advance\nits research or may affect its products adversely, (x) the effect of federal,\nstate, and foreign regulation, including drug regulation and international\ntrade regulation, on SIGA’s businesses, (xi) the impacts of significant\nrecent shifts in trade policies, including the imposition of tariffs,\nretaliatory tariff measures, and subsequent modifications or suspensions\nthereof, and market reactions to such policies and resulting trade disputes,\n(xii) the risk of disruptions to SIGA’s supply chain for the manufacture of\nTPOXX®, causing delays in SIGA’s research and development activities,\ncausing delays or the re-allocation of funding in connection with SIGA’s\ngovernment contracts, or diverting the attention of government staff\noverseeing SIGA’s government contracts, (xiii) risks associated with actions\nor uncertainties surrounding the debt ceiling, or the changes in U.S.\npolitical environment, and (xiv) the risk that the U.S. or foreign\ngovernments' responses (including inaction) to national or global economic\nconditions or infectious diseases, are ineffective and may adversely affect\nSIGA’s business, as well as the risks and uncertainties included in Item 1A\n“Risk Factors” of our Annual Report on Form 10-K for the year ended\nDecember 31, 2025 and SIGA's subsequent filings with the Securities and\nExchange Commission. SIGA urges investors and security holders to read those\ndocuments free of charge at the SEC's website at http://www.sec.gov. All such\nforward-looking statements are current only as of the date on which such\nstatements were made. SIGA does not undertake any obligation to update\npublicly any forward-looking statement to reflect events or circumstances\nafter the date on which any such statement is made or to reflect the\noccurrence of unanticipated events. \n\nInvestor and Media Contact\nSuzanne Harnett\nsharnett@siga.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/93028aa6-8191-4392-a7b1-447b046cd93b)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX960hxH-20261028","title":"SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX®","author":"Globe Newswire","ticker":"SIGA","created":"2026-10-28T11:30:00.136Z","tickers":["SIGA"],"exchange":"NASDAQ","article_body":"NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA)\n(Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced\nthat Public Services and Procurement Canada (PSPC) has awarded SIGA a new\ncontract for the procurement of oral TPOXX® (tecovirimat), an antiviral\nmedication used to treat smallpox, on behalf of the Canadian Department of\nNational Defence (CDND) through its Strategic Medical Countermeasures Program.\nThe contract provides for the purchase of up to approximately $15 million by\nMarch 31, 2031, of which approximately $9 million represents firm commitments\nover the first three years of the contract and approximately $6 million is\nsubject to option exercise by the CDND.\n\nThis contract is the second contract for TPOXX® awarded by PSPC on behalf of\nCDND. In April 2020, PSPC awarded a contract for the purchase of up to\napproximately $14 million of oral TPOXX®, and the final delivery under that\ncontract was made in 2025.\n\nCanada's Defence Industrial Strategy recognizes the importance of maintaining\naccess to critical medical countermeasures as part of Canada's broader health\nsecurity and defence preparedness objectives. By securing continued access to\nTPOXX®, this contract helps Canada deliver on that commitment while ensuring\nthat the Canadian Armed Forces have access to an approved medical\ncountermeasure against smallpox.\n\n\"Canada has been a consistent leader in smallpox preparedness, and this award\nreflects its sustained commitment to ensuring its military is ready to respond\nto a potential outbreak,\" said Diem Nguyen, Chief Executive Officer. \"Canadian\nArmed Forces members are often among the first called upon in a public health\nemergency, and ready access to an approved smallpox antiviral helps ensure\nthey can safely and effectively carry out that mission. We are proud to\ncontinue supporting Canada and look forward to further strengthening our\nrelationships with other governments around the world as we do our part to\nhelp protect populations from smallpox.\"\n\nOral TPOXX® was approved by Health Canada for the treatment of smallpox in\nNovember 2021.\n\nABOUT SIGA\n\nSIGA is a commercial-stage pharmaceutical company and leader in global health\nfocused on the development of innovative medicines to treat and prevent\ninfectious diseases. With a primary focus on smallpox, we are dedicated to\nprotecting humanity against the world’s most severe infectious diseases,\nincluding those that occur naturally, accidentally, or intentionally. Through\npartnerships with governments and public health agencies, we work to build a\nhealthier and safer world by providing essential countermeasures against these\nglobal health threats. For more information about SIGA, visit www.siga.com.\n\nFORWARD-LOOKING STATEMENTS\n\nThis press release contains “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act of 1995, as amended,\nincluding statements relating to SIGA’s future business development and\nplans. Forward-looking statements include statements regarding our future\nfinancial position, business strategy, budgets, projected costs, plans and\nobjectives of management for future operations, and delivering products to\ndomestic and international customers under procurement contracts. The words\n“may,” “continue,” “estimate,” “intend,” “plan,”\n“will,” “believe,” “project,” “expect,” “seek,”\n“anticipate,” “could,” “should,” “target,” “goal,”\n“potential” and similar expressions may identify forward-looking\nstatements, but the absence of these words does not necessarily mean that a\nstatement is not forward-looking. Such forward-looking statements are subject\nto various known and unknown risks and uncertainties, and SIGA cautions you\nthat any forward-looking information provided by or on behalf of SIGA is not a\nguarantee of future performance. SIGA’s actual results could differ\nmaterially from those anticipated by such forward-looking statements due to a\nnumber of factors, some of which are beyond SIGA’s control, including, but\nnot limited to, (i) the risk that SIGA is not able to secure in a timely\nmanner new contracts with the U.S. Government to substantially maintain or\nexpand the U.S. Government stockpile of TPOXX®, (ii) the risk that SIGA may\nnot complete remaining performance under the 19C BARDA Contract (the \"BARDA\nContract\"), with the U.S. Biomedical Advanced Research and Development\nAuthority (\"BARDA\") on schedule or in accordance with contractual terms, (iii)\nthe risk that the nascent international biodefense market does not develop to\na degree that allows SIGA to continue to successfully market TPOXX®\ninternationally, (iv) the risk that potential products, including potential\nalternative uses or formulations of TPOXX® that appear promising to SIGA or\nits collaborators, cannot be shown to be efficacious or safe in subsequent\npre-clinical or clinical trials, (v) the risk that target timing for\ndeliveries of product to customers, and the recognition of related revenues,\nare delayed or adversely impacted by the actions, or inaction, of contract\nmanufacturing organizations, or other vendors, within the supply chain, or due\nto coordination activities between the customer and supply chain vendors, (vi)\nthe risk that SIGA or its collaborators will not obtain or maintain\nappropriate or necessary governmental approvals to market these or other\npotential products or uses, (vii) the risk that any challenge to SIGA’s\npatent and other property rights, if adversely determined, could affect\nSIGA’s business and, even if determined favorably, could be costly, (viii)\nthe risk that regulatory requirements applicable to SIGA’s products may\nresult in the need for further or additional testing or documentation that\nwill delay or prevent SIGA from seeking, obtaining or maintaining needed\napprovals to market these products, (ix) the risk that changes in domestic or\nforeign economic and market conditions may affect SIGA’s ability to advance\nits research or may affect its products adversely, (x) the effect of federal,\nstate, and foreign regulation, including drug regulation and international\ntrade regulation, on SIGA’s businesses, (xi) the impacts of significant\nrecent shifts in trade policies, including the imposition of tariffs,\nretaliatory tariff measures, and subsequent modifications or suspensions\nthereof, and market reactions to such policies and resulting trade disputes,\n(xii) the risk of disruptions to SIGA’s supply chain for the manufacture of\nTPOXX®, causing delays in SIGA’s research and development activities,\ncausing delays or the re-allocation of funding in connection with SIGA’s\ngovernment contracts, or diverting the attention of government staff\noverseeing SIGA’s government contracts, (xiii) risks associated with actions\nor uncertainties surrounding the debt ceiling, or the changes in U.S.\npolitical environment, and (xiv) the risk that the U.S. or foreign\ngovernments' responses (including inaction) to national or global economic\nconditions or infectious diseases, are ineffective and may adversely affect\nSIGA’s business, as well as the risks and uncertainties included in Item 1A\n“Risk Factors” of our Annual Report on Form 10-K for the year ended\nDecember 31, 2025 and SIGA's subsequent filings with the Securities and\nExchange Commission. SIGA urges investors and security holders to read those\ndocuments free of charge at the SEC's website at http://www.sec.gov. All such\nforward-looking statements are current only as of the date on which such\nstatements were made. SIGA does not undertake any obligation to update\npublicly any forward-looking statement to reflect events or circumstances\nafter the date on which any such statement is made or to reflect the\noccurrence of unanticipated events. \n\nInvestor and Media Contact\nSuzanne Harnett\nsharnett@siga.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/93028aa6-8191-4392-a7b1-447b046cd93b)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-28T11:30:00.174930579Z","server_sent_at_ms":1793187000174},"received_at":"2026-10-28T11:30:00.228Z","source_url":null},"analysis":{"id":"170266","press_release_id":"182468","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":["majority of contract value (~$6M of $15M) is optional, not firm"],"eventType":"operations_update","narrative":"SIGA won a new Canadian government contract worth up to approximately $15 million to supply oral TPOXX to the Canadian Department of National Defence, with deliveries through March 31, 2031.\n\nApproximately $9 million is firmly committed over the first three years, with the remaining ~$6 million contingent on CDND option exercises. This is the second PSPC contract for TPOXX, following a ~$14 million award in April 2020 that was fully delivered by 2025.\n\nThe award adds to SIGA's international biodefense revenue base, though its near-term dollar value is small relative to the company's U.S. BARDA contract exposure.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Repeat Canadian defence order validates SIGA's international biodefense franchise, but only ~$9M of the $15M is firm."},"keyFigures":{"dealValueUsd":15000000,"customDimensions":{"option_value":"$6 million subject to CDND option exercise","firm_commitments":"$9 million over first three years","contract_deadline":"March 31, 2031"}},"quotedText":"Canada has been a consistent leader in smallpox preparedness, and this award reflects its sustained commitment to ensuring its military is ready to respond to a potential outbreak","namedEntities":{"people":[{"name":"Diem Nguyen","role":"CEO"}],"products":["TPOXX (tecovirimat)","oral TPOXX"],"companies":[{"name":"SIGA Technologies, Inc.","ticker":"SIGA","relationship":"filer/contract recipient"},{"name":"Public Services and Procurement Canada (PSPC)","relationship":"contracting authority"},{"name":"Canadian Department of National Defence (CDND)","relationship":"customer"},{"name":"Biomedical Advanced Research and Development Authority (BARDA)","relationship":"U.S. government contract partner"}],"dollarAmounts":[{"amount":"$15 million","context":"maximum contract value for TPOXX procurement through March 31, 2031"},{"amount":"$9 million","context":"firm commitments over first three years"},{"amount":"$6 million","context":"amount subject to option exercise by CDND"},{"amount":"$14 million","context":"prior April 2020 PSPC contract for oral TPOXX"}]},"materialImpact":{"score":2,"reasoning":"A new international government procurement contract worth up to ~$15M ($9M firm) is a modest revenue win for SIGA but small relative to the company's U.S. BARDA-centered business. Positive signal for international biodefense traction, not market-moving."},"tickerRelevance":{"others":[],"primary":"SIGA"},"globalImportance":25,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"modest government contract win","firmVsOptionalMix":"60% firm / 40% optional"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"SIGA won a new Canadian government contract worth up to approximately $15 million to supply oral TPOXX to the Canadian Department of National Defence, with deliveries through March 31, 2031.\n\nApproximately $9 million is firmly committed over the first three years, with the remaining ~$6 million contingent on CDND option exercises. This is the second PSPC contract for TPOXX, following a ~$14 million award in April 2020 that was fully delivered by 2025.\n\nThe award adds to SIGA's international biodefense revenue base, though its near-term dollar value is small relative to the company's U.S. BARDA contract exposure.","key_figures":{"dealValueUsd":15000000,"customDimensions":{"option_value":"$6 million subject to CDND option exercise","firm_commitments":"$9 million over first three years","contract_deadline":"March 31, 2031"}},"named_entities":{"people":[{"name":"Diem Nguyen","role":"CEO"}],"products":["TPOXX (tecovirimat)","oral TPOXX"],"companies":[{"name":"SIGA Technologies, Inc.","ticker":"SIGA","relationship":"filer/contract recipient"},{"name":"Public Services and Procurement Canada (PSPC)","relationship":"contracting authority"},{"name":"Canadian Department of National Defence (CDND)","relationship":"customer"},{"name":"Biomedical Advanced Research and Development Authority (BARDA)","relationship":"U.S. government contract partner"}],"dollarAmounts":[{"amount":"$15 million","context":"maximum contract value for TPOXX procurement through March 31, 2031"},{"amount":"$9 million","context":"firm commitments over first three years"},{"amount":"$6 million","context":"amount subject to option exercise by CDND"},{"amount":"$14 million","context":"prior April 2020 PSPC contract for oral TPOXX"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-28T11:30:08.009Z","global_importance":25,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"modest government contract win","firmVsOptionalMix":"60% firm / 40% optional"}},"durationMs":6273,"modelName":"glm-5.3-flashx"}}